An Overview of the DATA Waiver (X-Waiver) Changes

Episode Introduction: In January 2023, the federal DATA Waiver (X-Waiver) requirement was rescinded, expanding access to buprenorphine for the treatment of opioid use disorder. This is good news for patients who wish to seek treatment of substance use disorder. This is also good news for Osteopathic physicians who care for these patients and wish to treat them! Tune in to learn more about the regulation change and what to expect when renewing your DEA license.   Episode Summary: In today's episode of POMA DOes… James Latronica, DO sits down to explain recent regulation changes pertaining to the federal DATA Waiver (X-Waiver) regulation. He also explains the new attestation requirement for DEA license renewal, and provides clarity on the updated education requirements.   Key Takeaways: Barriers for prescribing buprenorphine have been recently removed, expanding access for the treatment of substance use disorder. Effective June 2023, updated education requirements are in place for DEA license renewal. Most physicians who have maintained their Pennsylvania unrestricted license since 2017 have met the new education requirement. Join POMA on June 8 for a "Buprenorphine Prescribing Crash Course" webinar to learn more about prescribing, dosing and monitoring, as well as the regulatory changes that went into effect in January 2023. Register today and earn free CME!   Find Us: Online: https://www.poma.org/ Email: [email protected] Facebook: https://www.facebook.com/POMADOs Instagram: https://www.instagram.com/pomados/ LinkedIn: https://www.linkedin.com/company/pennsylvania-osteopathic-medical-association/ Twitter: http://www.twitter.com/POMA_DOs YouTube: https://www.youtube.com/channel/UCbxG9QqV_7Hv2CEkJsE89ZA App Store: search Pa. Osteopathic Medical Assoc.